VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...
The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...
We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...
Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the ...
In this piece, we will take a look at where Merck & Co., Inc. (NYSE:MRK) ranks on the list of the top UBS AI and growth era. The stock market at the tail end […] We recently compiled a list of ...
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
Shares of Merck & Co. Inc. MRK inched 0.44% higher to $101.17 Thursday, on what proved to be an all-around mixed trading ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback